Long Position on QCOR @ $59.00 on 10/3/2013 (Fundamentals)

Questcor Pharmaceuticals (QCOR) is a biopharmaceutical company.

The Company provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications.

It primarily offers H.P. Acthar Gel, an injectable drug for the treatment of acute exacerbations of multiple sclerosis in adults; to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; and as monotherapy for the treatment of infantile spasms in infants and children under two years of age. The company’s H.P. Acthar Gel also focuses on rheumatology-related conditions, including collagen diseases and rheumatic disorders. In addition, it offers Doral for the treatment of insomnia.

The company sells its Acthar primarily to specialty pharmacies; and Doral to pharmaceutical wholesalers.

Shares are heading higher in an upward trading channel. Higher share prices are expected for this stock.

52-Week Trading Range: $17.60 - $74.76

Entry Point:  $59.00

Stop Loss:  $56.05

Target Price:   $64.90

Updates

10/8/2013 11:27:42 AM

QCOR fell below our stop loss. Position closed at $56.00.

Position closed on 10/8/2013 at price of $56.00 with a -5.08% loss in 5 days.

Back to Portfolio